Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 18/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 15/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 1.00 |
| ▸ | FAP | Q12884 | 13/20 | 1.00 |
| ▸ | PITRM1 | Q5JRX3 | 5/20 | 1.00 |
| ▸ | PREP | P48147 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talabostat SCHEMBL14160935 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL14160999 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL6895250 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL14160998 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL393024 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL12185345 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL4320843 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL23070729 | 0.93 | DPP4 (0.86) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL7417653 | 0.93 | DPP4 (0.86) | DPP4DPP7DPP8DPP9FAP | |
| Talabostat SCHEMBL4782073 | 0.93 | DPP4 (0.86) | DPP4DPP7DPP8DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230338402-A1 | TREATMENT REGIMEN FOR CANCER USING IMMUNOMODULATION | OAKTREE FUND ADMINISTRATION, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-10-19 | — | — | US | disclosed |
| WO-2023172958-A1 | STABLE FORMULATIONS OF TALABOSTAT | ONKOSXCEL THERAPEUTICS, LLC (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230258645-A1 | ANTXR1 AS A BIOMARKER OF IMMUNOSUPPRESSIVE FIBROBLAST POPULATIONS AND ITS USE FOR PREDICTING RESPONSE TO IMMUNOTHERAPY | INSTITUT CURIE (FR) | 2023-08-17 | — | — | US | disclosed |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-07-25 | — | — | US | disclosed |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2023-02-21 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220257759-A1 | TREATMENT OF SARCOMA USING IMMUNOMODULATION | OAKTREE FUND ADMINISTRATION, LLC | 2022-08-18 | — | — | US | disclosed |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330275-A1 | FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO | FAP, APC, FIBP | DPP4 147/4885DPP7 145/4885DPP8 223/4885 |
| US-11583516-B2 | Dash inhibitors, and uses related thereto | PCNA, CD2BP2, CCNO | DPP4 421/4885DPP7 130/4885DPP8 92/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
| US-11707539-B2 | FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto | FAP, APC, FIBP | DPP4 147/4885DPP7 145/4885DPP8 223/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885DPP7 2/4885DPP8 8/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | DPP4 3953/4885DPP7 4114/4885DPP8 3921/4885 |
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP4 1251/4885DPP7 910/4885DPP8 904/4885 |
| US-20190209525-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | DPP4 402/4885DPP7 127/4885DPP8 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.